CJC-1295 + Ipamorelin

10 mg blend

$69.99 CAD

A blend of two growth-hormone-axis research peptides whose published studies examined each component separately, not the combination.

Format: 10 mg blend
Use: Laboratory research

View cart

For laboratory research only · Not for human consumption

What is CJC-1295 + Ipamorelin?

This listing names CJC-1295, discussed as a long-acting analogue of growth-hormone-releasing hormone, together with ipamorelin, a pentapeptide described as a selective growth hormone secretagogue. They reach the same axis by different mechanisms.

Key concepts: Blend · Receptor · Agonist

How it works and what researchers study

Each component has its own literature. Growth-hormone-axis research measures hormone and IGF-I responses — in short randomized studies in healthy adults for CJC-1295, and in cell, rat and swine preparations for ipamorelin.

What the evidence shows

Studies of long-acting CJC-1295 given alone in healthy adults reported prolonged stimulation of growth hormone and IGF-I secretion. Ipamorelin was characterised as a selective growth hormone secretagogue with receptor pharmacology resembling growth-hormone-releasing peptides.

Limits of the evidence

The listing states a 10 mg blend. How that quantity is divided between components is not stated, so the ratio is unknown.
Whether the CJC-1295 component is the DAC (long-acting) form is supplier-specified and not stated here, so published long-acting pharmacology cannot be quoted as this product’s specification.
The cited studies do not demonstrate synergy, nor sleep, muscle or anti-ageing outcomes.

References

Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. doi:10.1210/jc.2005-1536 View source
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. doi:10.1530/eje.0.1390552 View source

Compound science vs product quality

The research described here studied the compound under laboratory or clinical conditions. No cited paper or label tested a Proof Line Peptides vial. Product-level questions — identity, stated quantity and lot-matched documentation — are answered by records supplied with the material, not by published studies.

Questions about CJC-1295 + Ipamorelin

Is the 10 mg split evenly between the two peptides?: That is not stated, so it should not be assumed. Component allocation is only known when documented.
Do the two components work the same way?: No. One is described as a growth-hormone-releasing hormone analogue, the other as a selective growth hormone secretagogue.
Does research on the components prove the blend works?: No. Component evidence supports statements about the components under the tested conditions, not about a combined preparation.